



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

BC HIV Treatment Program

Monthly Report
July 2025



FOREWORD

The British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) is a provincial treatment and research program, with the mandate to improve the health of people living with HIV (“PLWH”), and those at elevated risk of acquiring HIV in British Columbia (BC), by advancing and promoting programs for treatment and prevention of HIV, and related conditions, guided by Treatment as Prevention® (TasP®) principles. Funded by the BC’s Ministry of Health, through the province’s PharmaCare Program, the BC-CfE’s Drug Treatment Programs provide medications for HIV treatment, prevention, and select related conditions, at no charge, to medically eligible BC residents living with HIV, or at elevated risk of HIV acquisition. The provision of these medications are based on guidelines developed by the BC-CfE’s Committee for Drug Evaluation and Therapy (CDET) and program consideration.

A key component of the BC-CfE’s mandate is to monitor and evaluate its HIV Treatment Program, reporting on a regular basis and providing essential information to BC’s health authorities, treating clinicians, and the community at large. This HIV Treatment Program Report provides an overview of the use of antiretroviral medications in BC for the treatment of HIV, common drug combinations, key monitoring parameters, and distribution of program participants throughout the province.

Figures and graphs in this document are best viewed in colour.

Please note that any comments or queries regarding this report should be forwarded to info@bccfe.ca.

BC Centre for Excellence in HIV/AIDS Drug Treatment Programs

St. Paul’s Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through BC’s PharmaCare and Ministry of Health.

DISCLAIMER: All information presented in this report is generated from a secure, live database maintained by the BC-CfE. Privacy and confidentiality are matters which are taken very seriously and strict rules and procedures are applied to ensure that the information stored is secure.

Figures and tables provided in this report represent the best estimates at the time the document was generated, and may be subject to change. Please be advised that the information in this document is provided in good faith and is derived from sources understood to be accurate and up-to-date at the report’s date of publication.

© 2026 BC Centre for Excellence in HIV/AIDS



TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.3 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
- 1.7 Number of Participants on Protease Inhibitors by INGREDIENT
- 1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
- 1.11 Number of Participants on Integrase Inhibitors by INGREDIENT
- 1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (graph)
- 1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (table)
- 1.16 Percent Distribution of Active Participants by CD4 Count
- 1.17 Distribution of Active Participants by CD4 Count
- 1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (graph)
- 1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (table)
- 1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (graph)
- 1.21 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (table)
- 1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (graph)
- 1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (table)
- 1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance (graph)
- 1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance (table)

2. List of Tables

- 2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of January 2025
- 2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment
- 2.3 BC-CfE HIV Treatment Program Enrolment

3. Distribution of HIV Treatment Program Active Participants

- 3.1 Provincial Health Authorities
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

TABLE OF CONTENTS (continued)

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants by Age & Sex at Birth
- 4.2 Distribution of Participants by Program Duration
- 4.3 Distribution of Antiretroviral Treatment Prescribers

FRASER HEALTH

- 4.4 Distribution of Participants by Age & Sex at Birth
- 4.5 Distribution of Participants by Program Duration
- 4.6 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER COASTAL

- 4.7 Distribution of Participants by Age & Sex at Birth
- 4.8 Distribution of Participants by Program Duration
- 4.9 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER ISLAND

- 4.10 Distribution of Participants by Age & Sex at Birth
- 4.11 Distribution of Participants by Program Duration
- 4.12 Distribution of Antiretroviral Treatment Prescribers

NORTHERN HEALTH


- 4.13 Distribution of Participants by Age & Sex at Birth
- 4.14 Distribution of Participants by Program Duration
- 4.15 Distribution of Antiretroviral Treatment Prescribers

INDIGENOUS PARTICIPANTS

- 4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth



1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority July 2025
N = 7772




Health Authority	Male	Female	All
FRASER	1647	515	2162
VANCOUVER ISLAND	899	177	1076
VANCOUVER COASTAL	3202	443	3645
INTERIOR	496	125	621
NORTHERN	176	85	261
	6420	1345	7765
Unknown/not stated			7
Total			7772

On antiretroviral treatment is defined as being on treatment in the current month
Unknown/not stated is defined as being on treatment in the current month, and city of residence is unknown
Male & Female refer to Sex assigned at birth



1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
July 2020 - July 2025



1.3 Distribution of Participants in HIV Treatment Program by Regimen Category

MON-YYYY	Total	INSTI		Boosted PI		NNRTI		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
AUG-2023	7600	4773	62.8	643	8.5	621	8.2	864	11.4	632	8.3	67	0.9
SEP-2023	7609	4793	63.0	639	8.4	616	8.1	879	11.6	617	8.1	65	0.9
OCT-2023	7610	4808	63.2	615	8.1	611	8.0	897	11.8	618	8.1	61	0.8
NOV-2023	7612	4799	63.0	611	8.0	599	7.9	918	12.1	624	8.2	61	0.8
DEC-2023	7603	4808	63.2	593	7.8	596	7.8	936	12.3	614	8.1	56	0.7
JAN-2024	7642	4856	63.5	583	7.6	585	7.7	952	12.5	609	8.0	57	0.7
FEB-2024	7647	4861	63.6	564	7.4	586	7.7	971	12.7	609	8.0	56	0.7
MAR-2024	7636	4846	63.5	543	7.1	580	7.6	991	13.0	618	8.1	58	0.8
APR-2024	7670	4884	63.7	538	7.0	570	7.4	1000	13.0	621	8.1	57	0.7
MAY-2024	7687	4902	63.8	536	7.0	566	7.4	1023	13.3	607	7.9	53	0.7
JUN-2024	7687	4910	63.9	526	6.8	556	7.2	1033	13.4	606	7.9	56	0.7
JUL-2024	7718	4938	64.0	520	6.7	541	7.0	1060	13.7	605	7.8	54	0.7
AUG-2024	7709	4933	64.0	505	6.6	537	7.0	1081	14.0	602	7.8	51	0.7
SEP-2024	7697	4911	63.8	484	6.3	530	6.9	1124	14.6	595	7.7	53	0.7
OCT-2024	7725	4938	63.9	467	6.0	512	6.6	1167	15.1	593	7.7	48	0.6
NOV-2024	7703	4946	64.2	464	6.0	490	6.4	1176	15.3	581	7.5	46	0.6
DEC-2024	7720	4949	64.1	456	5.9	479	6.2	1199	15.5	588	7.6	49	0.6
JAN-2025	7739	4959	64.1	437	5.6	478	6.2	1234	15.9	586	7.6	45	0.6
FEB-2025	7696	4929	64.0	419	5.4	460	6.0	1264	16.4	577	7.5	47	0.6
MAR-2025	7689	4921	64.0	408	5.3	453	5.9	1291	16.8	572	7.4	44	0.6
APR-2025	7719	4947	64.1	394	5.1	432	5.6	1320	17.1	584	7.6	42	0.5
MAY-2025	7705	4911	63.7	386	5.0	423	5.5	1369	17.8	573	7.4	43	0.6
JUN-2025	7713	4893	63.4	371	4.8	417	5.4	1427	18.5	565	7.3	40	0.5
JUL-2025	7772	4940	63.6	359	4.6	411	5.3	1457	18.7	564	7.3	41	0.5

n is number of participants on the specified regimen class in the specified month


% is ratio of **n** and total number of participants on antiretroviral treatment in the specified month

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
July 2020 - July 2025






1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	abacavir		emtricitabine		lamivudine		tenofovir <TAF>		tenofovir <TDF>		zidovudine	
		n	%	n	%	n	%	n	%	n	%	n	%
AUG-2023	7467	1935	25.9	4561	61.1	2909	39.0	3717	49.8	969	13.0	14	0.2
SEP-2023	7478	1910	25.5	4578	61.2	2902	38.8	3746	50.1	954	12.8	13	0.2
OCT-2023	7474	1895	25.4	4573	61.2	2904	38.9	3766	50.4	935	12.5	14	0.2
NOV-2023	7474	1866	25.0	4585	61.4	2891	38.7	3783	50.6	918	12.3	15	0.2
DEC-2023	7464	1831	24.5	4595	61.6	2874	38.5	3820	51.2	895	12.0	13	0.2
JAN-2024	7502	1831	24.4	4633	61.8	2881	38.4	3866	51.5	890	11.9	13	0.2
FEB-2024	7504	1795	23.9	4641	61.9	2868	38.2	3896	51.9	864	11.5	13	0.2
MAR-2024	7493	1759	23.5	4656	62.1	2845	38.0	3927	52.4	844	11.3	13	0.2
APR-2024	7525	1742	23.2	4690	62.3	2844	37.8	3968	52.7	843	11.2	13	0.2
MAY-2024	7544	1706	22.6	4734	62.8	2822	37.4	4018	53.3	832	11.0	12	0.2
JUN-2024	7544	1691	22.4	4738	62.8	2817	37.3	4047	53.7	801	10.6	13	0.2
JUL-2024	7570	1667	22.0	4763	62.9	2812	37.2	4077	53.9	800	10.6	13	0.2
AUG-2024	7563	1633	21.6	4771	63.1	2796	37.0	4097	54.2	782	10.3	13	0.2
SEP-2024	7551	1600	21.2	4769	63.2	2797	37.0	4113	54.5	768	10.2	13	0.2
OCT-2024	7577	1556	20.5	4810	63.5	2789	36.8	4170	55.0	754	10.0	13	0.2
NOV-2024	7555	1499	19.8	4821	63.8	2744	36.3	4193	55.5	739	9.8	11	0.2
DEC-2024	7572	1481	19.6	4835	63.9	2756	36.4	4223	55.8	734	9.7	11	0.2
JAN-2025	7591	1431	18.9	4873	64.2	2740	36.1	4273	56.3	721	9.5	10	0.1
FEB-2025	7547	1370	18.2	4860	64.4	2698	35.8	4280	56.7	701	9.3	8	0.1
MAR-2025	7537	1335	17.7	4869	64.6	2680	35.6	4312	57.2	684	9.1	8	0.1
APR-2025	7557	1304	17.3	4909	65.0	2664	35.3	4374	57.9	655	8.7	6	0.1
MAY-2025	7537	1242	16.5	4894	64.9	2654	35.2	4373	58.0	630	8.4	7	0.1
JUN-2025	7540	1196	15.9	4910	65.1	2647	35.1	4406	58.4	620	8.2	7	0.1
JUL-2025	7593	1137	15.0	4981	65.6	2629	34.6	4482	59.0	615	8.1	7	0.1

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
July 2020 - July 2025




1.7 Number of Participants on Protease Inhibitors by INGREDIENT

MON-YYYY	Total Participants	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
		n	%	n	%	n	%	n	%	n	%
AUG-2023	1225	276	22.5	914	74.6	36	2.9	0	0.0	0	0.00
SEP-2023	1214	271	22.3	909	74.9	35	2.9	0	0.0	0	0.00
OCT-2023	1198	273	22.8	893	74.5	35	2.9	0	0.0	0	0.00
NOV-2023	1184	260	22.0	890	75.2	35	3.0	0	0.0	0	0.00
DEC-2023	1156	248	21.5	876	75.8	33	2.9	0	0.0	0	0.00
JAN-2024	1138	241	21.2	866	76.1	33	2.9	0	0.0	0	0.00
FEB-2024	1111	229	20.6	852	76.7	31	2.8	0	0.0	0	0.00
MAR-2024	1094	225	20.6	840	76.8	30	2.7	0	0.0	0	0.00
APR-2024	1088	224	20.6	835	76.8	31	2.9	0	0.0	0	0.00
MAY-2024	1081	221	20.4	828	76.6	33	3.1	0	0.0	0	0.00
JUN-2024	1059	214	20.2	813	76.8	33	3.1	0	0.0	0	0.00
JUL-2024	1052	216	20.5	805	76.5	33	3.1	0	0.0	0	0.00
AUG-2024	1021	208	20.4	784	76.8	31	3.0	0	0.0	0	0.00
SEP-2024	1001	203	20.3	772	77.1	27	2.7	0	0.0	0	0.00
OCT-2024	977	197	20.2	754	77.2	27	2.8	0	0.0	0	0.00
NOV-2024	957	190	19.9	742	77.5	28	2.9	0	0.0	0	0.00
DEC-2024	947	184	19.4	738	77.9	26	2.8	0	0.0	0	0.00
JAN-2025	922	177	19.2	726	78.7	23	2.5	0	0.0	0	0.00
FEB-2025	891	168	18.9	700	78.6	24	2.7	0	0.0	0	0.00
MAR-2025	875	167	19.1	686	78.4	24	2.7	0	0.0	0	0.00
APR-2025	860	153	17.8	684	79.5	24	2.8	0	0.0	0	0.00
MAY-2025	840	151	18.0	666	79.3	24	2.9	0	0.0	0	0.00
JUN-2025	823	150	18.2	652	79.2	23	2.8	0	0.0	0	0.00
JUL-2025	806	146	18.1	639	79.3	23	2.9	0	0.0	0	0.00

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Ritonavir - greater than 400 mg total daily dose

1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
July 2020 - July 2025




1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	doravirine n %	efavirenz n %	etravirine n %	nevirapine n %	rilpivirine n %
AUG-2023	951	238 25.0	222 23.3	91 9.6	223 23.5	182 19.1
SEP-2023	938	236 25.2	218 23.2	88 9.4	220 23.5	177 18.9
OCT-2023	932	238 25.5	216 23.2	89 9.6	220 23.6	173 18.6
NOV-2023	928	242 26.1	209 22.5	88 9.5	219 23.6	173 18.6
DEC-2023	929	250 26.9	205 22.1	87 9.4	213 22.9	176 19.0
JAN-2024	921	250 27.1	200 21.7	83 9.0	208 22.6	181 19.7
FEB-2024	919	257 28.0	192 20.9	82 8.9	207 22.5	182 19.8
MAR-2024	914	260 28.5	190 20.8	80 8.8	205 22.4	181 19.8
APR-2024	915	261 28.5	190 20.8	82 9.0	203 22.2	180 19.7
MAY-2024	906	262 28.9	186 20.5	80 8.8	205 22.6	175 19.3
JUN-2024	893	262 29.3	182 20.4	79 8.9	198 22.2	172 19.3
JUL-2024	890	270 30.3	176 19.8	78 8.8	194 21.8	172 19.3
AUG-2024	879	272 30.9	174 19.8	78 8.9	187 21.3	171 19.5
SEP-2024	886	275 31.0	172 19.4	76 8.6	185 20.9	179 20.2
OCT-2024	871	283 32.5	168 19.3	72 8.3	177 20.3	175 20.1
NOV-2024	850	287 33.8	162 19.1	70 8.2	159 18.7	173 20.4
DEC-2024	844	303 35.9	156 18.5	71 8.4	149 17.7	167 19.8
JAN-2025	844	309 36.6	157 18.6	67 7.9	143 16.9	172 20.4
FEB-2025	834	306 36.7	156 18.7	64 7.7	136 16.3	173 20.7
MAR-2025	823	311 37.8	147 17.9	62 7.5	132 16.0	173 21.0
APR-2025	818	317 38.8	137 16.8	61 7.5	128 15.7	177 21.6
MAY-2025	809	313 38.7	129 16.0	60 7.4	126 15.6	181 22.4
JUN-2025	812	315 38.8	127 15.6	60 7.4	122 15.0	190 23.4
JUL-2025	809	322 39.8	124 15.3	56 6.9	113 14.0	194 24.0

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class

1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
July 2020 - July 2025






1.11 Number of Participants on Integrase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	bictegravir n %	cabotegravir n %	dolutegravir n %	elvitegravir n %	raltegravir n %
AUG-2023	6240	3258 52.2	7 0.1	2495 40.0	245 3.9	253 4.1
SEP-2023	6263	3289 52.5	8 0.1	2500 39.9	238 3.8	249 4.0
OCT-2023	6294	3298 52.4	7 0.1	2523 40.1	241 3.8	248 3.9
NOV-2023	6311	3327 52.7	9 0.1	2518 39.9	233 3.7	244 3.9
DEC-2023	6330	3365 53.2	13 0.2	2506 39.6	226 3.6	237 3.7
JAN-2024	6389	3418 53.5	16 0.3	2520 39.4	224 3.5	234 3.7
FEB-2024	6417	3453 53.8	15 0.2	2516 39.2	219 3.4	231 3.6
MAR-2024	6435	3498 54.4	17 0.3	2500 38.9	220 3.4	225 3.5
APR-2024	6483	3545 54.7	17 0.3	2497 38.5	216 3.3	225 3.5
MAY-2024	6511	3586 55.1	19 0.3	2488 38.2	213 3.3	222 3.4
JUN-2024	6528	3614 55.4	21 0.3	2488 38.1	207 3.2	218 3.3
JUL-2024	6584	3650 55.4	25 0.4	2500 38.0	212 3.2	213 3.2
AUG-2024	6593	3683 55.9	26 0.4	2487 37.7	204 3.1	207 3.1
SEP-2024	6610	3700 56.0	32 0.5	2495 37.8	200 3.0	205 3.1
OCT-2024	6680	3757 56.2	34 0.5	2508 37.5	198 3.0	199 3.0
NOV-2024	6681	3791 56.7	33 0.5	2487 37.2	191 2.9	193 2.9
DEC-2024	6720	3819 56.8	33 0.5	2521 37.5	185 2.8	187 2.8
JAN-2025	6762	3866 57.2	36 0.5	2525 37.3	185 2.7	179 2.7
FEB-2025	6754	3883 57.5	41 0.6	2495 36.9	183 2.7	176 2.6
MAR-2025	6767	3913 57.8	48 0.7	2481 36.7	181 2.7	175 2.6
APR-2025	6834	3985 58.3	49 0.7	2488 36.4	176 2.6	167 2.4
MAY-2025	6840	3987 58.3	57 0.8	2478 36.2	174 2.5	165 2.4
JUN-2025	6868	4021 58.6	67 1.0	2483 36.2	170 2.5	162 2.4
JUL-2025	6952	4102 59.0	75 1.1	2478 35.6	168 2.4	159 2.3

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
July 2020 - July 2025






1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT

MON-YYYY	Total Participants	fostemsavir		maraviroc		lenacapavir	
		n	%	n	%	n	%
AUG-2023	20	2	10.0	18	90.0	0	0.0
SEP-2023	20	2	10.0	18	90.0	0	0.0
OCT-2023	20	2	10.0	18	90.0	1	5.0
NOV-2023	19	1	5.3	17	89.5	1	5.3
DEC-2023	19	2	10.5	16	84.2	1	5.3
JAN-2024	21	2	9.5	18	85.7	1	4.8
FEB-2024	21	2	9.5	18	85.7	1	4.8
MAR-2024	21	3	14.3	17	81.0	2	9.5
APR-2024	22	2	9.1	18	81.8	2	9.1
MAY-2024	19	2	10.5	15	79.0	2	10.5
JUN-2024	21	2	9.5	17	81.0	2	9.5
JUL-2024	21	2	9.5	17	81.0	2	9.5
AUG-2024	21	2	9.5	17	81.0	2	9.5
SEP-2024	20	2	10.0	16	80.0	2	10.0
OCT-2024	20	2	10.0	15	75.0	3	15.0
NOV-2024	20	2	10.0	16	80.0	2	10.0
DEC-2024	20	2	10.0	16	80.0	2	10.0
JAN-2025	20	2	10.0	16	80.0	2	10.0
FEB-2025	19	2	10.5	15	79.0	2	10.5
MAR-2025	19	2	10.5	15	79.0	2	10.5
APR-2025	19	2	10.5	15	79.0	2	10.5
MAY-2025	17	2	11.8	14	82.4	1	5.9
JUN-2025	19	2	10.5	15	79.0	2	10.5
JUL-2025	22	2	9.1	16	72.7	4	18.2

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Both lenacapavir and fostemsavir are currently not on BC-CfE Formulary



1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals
July 2020 - July 2025




1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals

MON-YYYY	Total Participants	1 drug		2 drugs		3 drugs		4 drugs		5 or more drugs	
		n	%	n	%	n	%	n	%	n	%
AUG-2023	7600	2	0.0	864	11.4	6240	82.1	448	5.9	46	0.6
SEP-2023	7609	2	0.0	879	11.6	6250	82.1	432	5.7	46	0.6
OCT-2023	7610	2	0.0	897	11.8	6237	82.0	433	5.7	41	0.5
NOV-2023	7612	2	0.0	918	12.1	6210	81.6	441	5.8	41	0.5
DEC-2023	7603	2	0.0	936	12.3	6191	81.4	434	5.7	40	0.5
JAN-2024	7642	2	0.0	952	12.5	6214	81.3	432	5.7	42	0.6
FEB-2024	7647	3	0.0	971	12.7	6198	81.1	436	5.7	39	0.5
MAR-2024	7636	2	0.0	991	13.0	6159	80.7	440	5.8	44	0.6
APR-2024	7670	2	0.0	1001	13.1	6184	80.6	437	5.7	46	0.6
MAY-2024	7687	2	0.0	1024	13.3	6188	80.5	434	5.7	39	0.5
JUN-2024	7687	1	0.0	1034	13.5	6181	80.4	429	5.6	42	0.6
JUL-2024	7718	2	0.0	1061	13.8	6184	80.1	434	5.6	37	0.5
AUG-2024	7709	2	0.0	1082	14.0	6155	79.8	431	5.6	39	0.5
SEP-2024	7697	2	0.0	1125	14.6	6101	79.3	426	5.5	43	0.6
OCT-2024	7725	1	0.0	1169	15.1	6087	78.8	427	5.5	41	0.5
NOV-2024	7703	1	0.0	1177	15.3	6069	78.8	417	5.4	39	0.5
DEC-2024	7720	2	0.0	1200	15.5	6054	78.4	424	5.5	40	0.5
JAN-2025	7739	2	0.0	1235	16.0	6047	78.1	416	5.4	39	0.5
FEB-2025	7696	2	0.0	1265	16.4	5977	77.7	414	5.4	38	0.5
MAR-2025	7689	4	0.1	1292	16.8	5942	77.3	414	5.4	37	0.5
APR-2025	7719	3	0.0	1321	17.1	5939	76.9	419	5.4	37	0.5
MAY-2025	7705	4	0.1	1370	17.8	5882	76.3	410	5.3	39	0.5
JUN-2025	7713	4	0.1	1428	18.5	5845	75.8	396	5.1	40	0.5
JUL-2025	7772	2	0.0	1460	18.8	5874	75.6	399	5.1	37	0.5

n is the number of individual drugs in antiretroviral treatment regimen (excluding low dose ritonavir and cobicistat used for pharmacokinetic boosting)



1.16 Percent Distribution of Active Participants by CD4 Count
July 2020 - July 2025



1.17 Distribution of Active Participants by CD4 Count

Month	# of Pts with CD4: Unreported	# of Pts with CD4: < 200	# of Pts with CD4: 200 - 349	# of Pts with CD4: 350 - 500	# of Pts with CD4: > 500
AUG-2023	1262	254	560	943	3767
SEP-2023	1316	243	547	951	3744
OCT-2023	1365	242	543	943	3727
NOV-2023	1400	237	542	937	3689
DEC-2023	1444	237	530	917	3703
JAN-2024	1481	238	529	916	3679
FEB-2024	1519	242	503	911	3673
MAR-2024	1550	255	498	924	3649
APR-2024	1593	253	486	944	3627
MAY-2024	1626	248	486	923	3661
JUN-2024	1665	247	493	886	3679
JUL-2024	1726	248	493	912	3681
AUG-2024	1771	251	491	910	3659
SEP-2024	1789	241	489	935	3638
OCT-2024	1823	243	499	948	3624
NOV-2024	1856	234	505	917	3652
DEC-2024	1885	232	508	928	3658
JAN-2025	1912	233	509	939	3650
FEB-2025	1934	223	511	930	3640
MAR-2025	1955	225	508	934	3620
APR-2025	1993	230	500	903	3666
MAY-2025	2018	229	492	876	3652
JUN-2025	2056	224	476	900	3652
JUL-2025	2117	215	508	884	3694

CD4 value (cells/μL) as per the most recent test within the past 12 months

CD4 Unreported: CD4 not tested or reported within the past 12 months

Active Participants are participants with antiretroviral treatment in the month based on dispensing record



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS




**Providence
Health Care**



Ministry of
Health

1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment
July 2020 - July 2025




1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment

MON-YYYY	Total	INSTI 2 N(t)RTIs		Boosted PI 2 N(t)RTIs		NNRTI 2 N(t)RTIs		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
AUG-2023	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
SEP-2023	5	5	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2023	10	9	90.0	0	0.0	0	0.0	1	10.0	0	0.0	0	0.0
NOV-2023	9	7	77.8	0	0.0	0	0.0	1	11.1	1	11.1	0	0.0
DEC-2023	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
JAN-2024	11	9	81.8	0	0.0	0	0.0	0	0.0	2	18.2	0	0.0
FEB-2024	11	11	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2024	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
APR-2024	20	18	90.0	0	0.0	0	0.0	0	0.0	2	10.0	0	0.0
MAY-2024	16	16	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2024	23	22	95.7	0	0.0	0	0.0	0	0.0	1	4.3	0	0.0
JUL-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
AUG-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SEP-2024	7	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
NOV-2024	9	8	88.9	0	0.0	1	11.1	0	0.0	0	0.0	0	0.0
DEC-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JAN-2025	14	14	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
FEB-2025	9	9	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
APR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAY-2025	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2025	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUL-2025	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor, **N(t)RTI:** Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor
n is number of participants on the specified regimen category in the specified month
% is ratio of n and total number of participants initiating antiretroviral treatment in the specified month



1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program
July 2020 - July 2025




1.21 Pre-entry CD4 for Antiretroviral Treatment Naive Participants in the HIV Treatment Program

MON-YYYY	# of First Starts	# of Pts with CD4: Unreported		# of Pts with CD4: < 200		# of Pts with CD4: 200 - 349		# of Pts with CD4: 350 - 500		# of Pts with CD4: > 500	
		n	%	n	%	n	%	n	%	n	%
AUG-2023	13	2	15.4	3	23.1	4	30.8	2	15.4	2	15.4
SEP-2023	5	0	0.0	2	40.0	0	0.0	0	0.0	3	60.0
OCT-2023	10	1	10.0	1	10.0	3	30.0	2	20.0	3	30.0
NOV-2023	9	1	11.1	2	22.2	0	0.0	2	22.2	4	44.4
DEC-2023	13	1	7.7	1	7.7	3	23.1	0	0.0	8	61.5
JAN-2024	11	1	9.1	4	36.4	2	18.2	1	9.1	3	27.3
FEB-2024	11	1	9.1	3	27.3	4	36.4	2	18.2	1	9.1
MAR-2024	13	2	15.4	5	38.5	1	7.7	1	7.7	4	30.8
APR-2024	20	0	0.0	4	20.0	6	30.0	1	5.0	9	45.0
MAY-2024	16	1	6.3	5	31.3	3	18.8	1	6.3	6	37.5
JUN-2024	23	0	0.0	2	8.7	10	43.5	4	17.4	7	30.4
JUL-2024	10	1	10.0	1	10.0	3	30.0	3	30.0	2	20.0
AUG-2024	15	0	0.0	5	33.3	4	26.7	3	20.0	3	20.0
SEP-2024	7	0	0.0	1	14.3	4	57.1	1	14.3	1	14.3
OCT-2024	15	0	0.0	6	40.0	3	20.0	3	20.0	3	20.0
NOV-2024	9	0	0.0	3	33.3	3	33.3	2	22.2	1	11.1
DEC-2024	10	0	0.0	4	40.0	2	20.0	2	20.0	2	20.0
JAN-2025	14	0	0.0	6	42.9	2	14.3	5	35.7	1	7.1
FEB-2025	9	0	0.0	2	22.2	1	11.1	3	33.3	3	33.3
MAR-2025	12	1	8.3	5	41.7	2	16.7	2	16.7	2	16.7
APR-2025	12	1	8.3	3	25.0	2	16.7	2	16.7	4	33.3
MAY-2025	17	1	5.9	6	35.3	3	17.7	5	29.4	2	11.8
JUN-2025	8	0	0.0	2	25.0	3	37.5	2	25.0	1	12.5
JUL-2025	8	2	25.0	0	0.0	2	25.0	2	25.0	2	25.0

First Starts defined as participants starting antiretroviral treatment in the specified month for the first time (antiretroviral treatment naive)
Pre-entry CD4 (cells/ μ L) is defined as most recent CD4 test before antiretroviral treatment start

1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment
July 2020 - July 2025



1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment

MON-YYYY	On Antiretroviral (ARV) Treatment	Ever Tested	NNRTI		N(t)RTI		PI		INSTI	
			n	%	n	%	n	%	n	%
AUG-2023	7577	6421	1313	20.5	1664	25.9	557	8.7	107	1.7
SEP-2023	7579	6406	1304	20.4	1645	25.7	557	8.7	104	1.6
OCT-2023	7579	6394	1307	20.4	1648	25.8	552	8.6	99	1.6
NOV-2023	7578	6388	1307	20.5	1644	25.7	558	8.7	101	1.6
DEC-2023	7574	6374	1306	20.5	1634	25.6	553	8.7	100	1.6
JAN-2024	7613	6399	1306	20.4	1645	25.7	549	8.6	102	1.6
FEB-2024	7620	6409	1301	20.3	1647	25.7	562	8.8	102	1.6
MAR-2024	7616	6393	1294	20.2	1638	25.6	555	8.7	105	1.6
APR-2024	7647	6411	1299	20.3	1637	25.5	563	8.8	102	1.6
MAY-2024	7666	6419	1301	20.3	1637	25.5	566	8.8	103	1.6
JUN-2024	7678	6419	1306	20.4	1626	25.3	560	8.7	101	1.6
JUL-2024	7697	6425	1315	20.5	1636	25.5	557	8.7	107	1.7
AUG-2024	7686	6410	1304	20.3	1620	25.3	547	8.5	105	1.6
SEP-2024	7674	6391	1299	20.3	1622	25.4	553	8.7	102	1.6
OCT-2024	7702	6408	1285	20.1	1618	25.3	555	8.7	99	1.5
NOV-2024	7674	6374	1279	20.1	1614	25.3	544	8.5	97	1.5
DEC-2024	7693	6373	1279	20.1	1601	25.1	541	8.5	101	1.6
JAN-2025	7712	6374	1272	20.0	1588	24.9	529	8.3	105	1.7
FEB-2025	7673	6328	1268	20.0	1575	24.9	530	8.4	106	1.7
MAR-2025	7668	6327	1259	19.9	1561	24.7	531	8.4	108	1.7
APR-2025	7702	6345	1263	19.9	1569	24.7	524	8.3	104	1.6
MAY-2025	7676	6322	1265	20.0	1561	24.7	529	8.4	104	1.7
JUN-2025	7692	6321	1262	20.0	1554	24.6	521	8.2	104	1.7
JUL-2025	7749	6359	1265	19.9	1559	24.5	520	8.2	105	1.7

On Antiretroviral (ARV) Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever Tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the month of interest.

n: number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug in the corresponding drug class in BC. Participants may have resistance to none or 1 or more drug class(es).

% is calculated as ratio of "n" and number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug the corresponding drug class in BC.


Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8. HIVdb scores ≥ 15 are classified as "resistant".

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance
July 2020 - July 2025



1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance

MON-YYYY	On Antiretroviral Treatment	Ever Tested	0-Class (Wild Type)		1-Class		2-Class		3 or more Class	
			n	%	n	%	n	%	n	%
AUG-2023	7577	6421	4097	63.8	1287	20.0	761	11.9	276	4.3
SEP-2023	7579	6406	4098	64.0	1281	20.0	755	11.8	272	4.3
OCT-2023	7579	6394	4086	63.9	1282	20.1	758	11.9	268	4.2
NOV-2023	7578	6388	4076	63.8	1288	20.2	754	11.8	270	4.2
DEC-2023	7574	6374	4070	63.9	1287	20.2	749	11.8	268	4.2
JAN-2024	7613	6399	4087	63.9	1293	20.2	751	11.7	268	4.2
FEB-2024	7620	6409	4098	63.9	1285	20.1	755	11.8	271	4.2
MAR-2024	7616	6393	4096	64.1	1277	20.0	749	11.7	271	4.2
APR-2024	7647	6411	4103	64.0	1292	20.2	743	11.6	273	4.3
MAY-2024	7666	6419	4107	64.0	1292	20.1	749	11.7	271	4.2
JUN-2024	7678	6419	4117	64.1	1286	20.0	743	11.6	273	4.3
JUL-2024	7697	6425	4110	64.0	1294	20.1	746	11.6	275	4.3
AUG-2024	7686	6410	4115	64.2	1288	20.1	737	11.5	270	4.2
SEP-2024	7674	6391	4098	64.1	1286	20.1	735	11.5	272	4.3
OCT-2024	7702	6408	4120	64.3	1288	20.1	734	11.5	266	4.2
NOV-2024	7674	6374	4098	64.3	1282	20.1	732	11.5	262	4.1
DEC-2024	7693	6373	4104	64.4	1277	20.0	733	11.5	259	4.1
JAN-2025	7712	6374	4115	64.6	1277	20.0	731	11.5	251	3.9
FEB-2025	7673	6328	4078	64.4	1274	20.1	724	11.4	252	4.0
MAR-2025	7668	6327	4086	64.6	1276	20.2	715	11.3	250	4.0
APR-2025	7702	6345	4104	64.7	1274	20.1	718	11.3	249	3.9
MAY-2025	7676	6322	4082	64.6	1273	20.1	718	11.4	249	3.9
JUN-2025	7692	6321	4091	64.7	1268	20.1	716	11.3	246	3.9
JUL-2025	7749	6359	4121	64.8	1276	20.1	716	11.3	246	3.9

Number of Antiretroviral (ARV) Drug Classes with Resistance considers N(t)RTIs, NNRTIs, PIs, and INSTIs only, based on cumulative resistance tests performed in BC (until the specified month) for participants ever tested (see definition below).

Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8.

HIVdb scores ≥ 15 are classified as "resistant".

On Antiretroviral Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the specified month.





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of July 2025

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
Pre-1993	31	48	183	174	9	34	(30, 39)	89	550	(360, 740)	165	<40	(<40, <40)
1993	30	119	120	106	14	34	(29, 39)	74	620	(415, 810)	114	<40	(<40, <40)
1994	29	68	68	58	10	35	(30, 38)	44	630	(440, 840)	63	<40	(<40, <40)
1995	28	123	124	106	18	34	(29, 39)	72	615	(455, 785)	113	<40	(<40, <40)
1996	26	315	317	275	42	35	(30, 39)	180	620	(430, 833)	281	<40	(<40, <40)
1997	24	262	268	244	24	34	(30, 38)	159	600	(405, 855)	236	<40	(<40, <40)
1998	24	182	191	159	32	34	(30, 40)	128	590	(428, 780)	173	<40	(<40, <40)
1999	24	165	166	129	37	36	(30, 42)	113	600	(380, 830)	148	<40	(<40, <40)
2000	24	118	121	98	23	38	(34, 44)	74	650	(455, 825)	110	<40	(<40, <40)
2001	23	120	122	97	25	37	(30, 44)	77	600	(380, 790)	111	<40	(<40, <40)
2002	22	118	128	110	18	40	(31, 46)	78	545	(440, 738)	116	<40	(<40, <40)
2003	22	140	150	126	24	39	(34, 46)	96	575	(425, 793)	123	<40	(<40, <40)
2004	21	143	165	128	37	40	(35, 44)	110	625	(393, 798)	156	<40	(<40, <40)
2005	20	180	197	157	40	40	(35, 47)	140	660	(460, 880)	178	<40	(<40, <40)
2006	19	177	197	160	37	41	(33, 48)	137	630	(460, 810)	179	<40	(<40, <40)
2007	18	232	251	218	33	41	(35, 46)	170	660	(463, 838)	225	<40	(<40, <40)
2008	17	273	307	250	57	42	(35, 49)	225	680	(500, 900)	271	<40	(<40, <40)
2009	16	300	331	274	57	41	(34, 47)	221	660	(450, 920)	293	<40	(<40, <40)
2010	15	263	304	241	63	40	(32, 45)	218	660	(483, 830)	273	<40	(<40, <40)
2011	14	315	358	291	67	41	(34, 48)	233	710	(490, 900)	314	<40	(<40, <40)
2012	13	280	315	256	59	40	(32, 49)	200	740	(548, 953)	284	<40	(<40, <40)
2013	12	245	294	237	57	40	(32, 49)	188	685	(488, 893)	255	<40	(<40, <40)
2014	11	225	294	249	45	40	(31, 50)	189	760	(550, 990)	256	<40	(<40, <40)
2015	10	199	282	241	41	41	(31, 51)	186	695	(500, 920)	257	<40	(<40, <40)
2016	9	178	252	208	44	39	(32, 49)	163	670	(485, 910)	211	<40	(<40, <40)
2017	8	155	224	191	33	36	(28, 45)	157	680	(510, 930)	211	<40	(<40, <40)
2018	7	139	213	167	46	39	(31, 48)	140	785	(556, 983)	181	<40	(<40, <40)
2019	6	130	246	204	42	38	(29, 48)	186	735	(530, 900)	217	<40	(<40, <40)
2020	5	106	204	153	51	37	(30, 48)	161	720	(530, 910)	176	<40	(<40, <40)

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
 CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of July 2025 (cont.)

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
2021	4	109	201	171	30	37	(30, 47)	177	650	(440, 850)	141	<40	(<40, <40)
2022	3	110	274	225	49	38	(31, 47)	258	680	(540, 940)	206	<40	(<40, <40)
2023	2	114	314	256	58	35	(30, 45)	282	640	(460, 830)	242	<40	(<40, <40)
2024	1	136	355	283	72	36	(29, 45)	326	605	(440, 810)	308	<40	(<40, <40)
2025	0	75	213	162	51	36	(30, 46)	208	580	(360, 770)	201	<40	(<40, <40)
Total:		5862	7749	6404	1345								

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively



2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment

MON-YYYY	Total Participants	Median # of Treatment days	CD4 (cells/ μ L)			pVL (copies/mL)		
			(n)	Median	(Q1, Q3)	(n)	Median	(Q1, Q3)
AUG-2023	7600	804	5524	641	(450, 860)	6890	<40	(<40, <40)
SEP-2023	7609	796	5485	650	(450, 860)	6893	<40	(<40, <40)
OCT-2023	7610	803	5455	640	(450, 860)	6812	<40	(<40, <40)
NOV-2023	7612	795	5405	640	(450, 860)	6841	<40	(<40, <40)
DEC-2023	7603	798	5387	650	(460, 860)	6829	<40	(<40, <40)
JAN-2024	7642	792	5362	640	(460, 860)	6815	<40	(<40, <40)
FEB-2024	7647	781	5329	650	(460, 870)	6865	<40	(<40, <40)
MAR-2024	7636	790	5326	640	(450, 870)	6872	<40	(<40, <40)
APR-2024	7670	786	5310	640	(450, 870)	6843	<40	(<40, <40)
MAY-2024	7687	787	5318	650	(460, 880)	6897	<40	(<40, <40)
JUN-2024	7687	784	5305	650	(460, 870)	6922	<40	(<40, <40)
JUL-2024	7718	786	5334	650	(460, 870)	7010	<40	(<40, <40)
AUG-2024	7709	782	5311	650	(460, 870)	6938	<40	(<40, <40)
SEP-2024	7697	791	5303	650	(460, 870)	6905	<40	(<40, <40)
OCT-2024	7725	787	5314	650	(460, 870)	6899	<40	(<40, <40)
NOV-2024	7703	793	5308	650	(460, 880)	6876	<40	(<40, <40)
DEC-2024	7720	796	5326	650	(460, 880)	6914	<40	(<40, <40)
JAN-2025	7739	792	5331	650	(450, 880)	6883	<40	(<40, <40)
FEB-2025	7696	800	5304	650	(460, 880)	6871	<40	(<40, <40)
MAR-2025	7689	792	5287	650	(450, 875)	6813	<40	(<40, <40)
APR-2025	7719	779	5299	660	(460, 880)	6891	<40	(<40, <40)
MAY-2025	7705	787	5249	660	(460, 880)	6861	<40	(<40, <40)
JUN-2025	7713	785	5252	660	(460, 880)	6835	<40	(<40, <40)
JUL-2025	7772	773	5301	652	(460, 870)	6914	<40	(<40, <40)

Active participant defined as being on antiretroviral treatment in the specified month

Treatment days defined as number of consecutive days on antiretroviral treatment (most recent uninterrupted period)

CD4 and pVL tests defined as tests done in the specified month



2.3 BC-CfE HIV Treatment Program Enrolment

MON-YYYY	On ARV Treatment	Off ARV Treatment	Deceased	ARV Treatment naïve starts	ARV Treatment experienced starts	Newly interrupted ARV Treatment	Net Change
AUG-2023	7577	728	11	13	217	192	22
SEP-2023	7579	715	14	5	179	163	2
OCT-2023	7579	725	18	10	170	160	0
NOV-2023	7578	732	18	9	182	171	-1
DEC-2023	7574	741	14	13	169	169	-4
JAN-2024	7613	699	16	11	204	159	39
FEB-2024	7620	696	17	11	184	165	7
MAR-2024	7616	710	12	13	183	185	-4
APR-2024	7647	693	17	20	197	168	31
MAY-2024	7666	692	12	16	191	173	19
JUN-2024	7678	707	5	23	173	177	12
JUL-2024	7697	696	15	10	185	159	19
AUG-2024	7686	711	13	15	164	168	-11
SEP-2024	7674	717	9	7	182	186	-12
OCT-2024	7702	710	8	15	200	172	28
NOV-2024	7674	747	14	9	181	199	-28
DEC-2024	7693	744	15	10	194	170	19
JAN-2025	7712	717	14	14	196	170	19
FEB-2025	7673	760	10	9	166	201	-39
MAR-2025	7668	760	12	12	175	177	-5
APR-2025	7702	737	9	12	192	157	34
MAY-2025	7676	758	18	17	167	188	-26
JUN-2025	7692	737	12	8	175	150	16
JUL-2025	7749	697	8	8	203	141	57

ARV: antiretroviral

On ARV Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program

Off ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month and not deceased or moved out of program

Deceased: in the specified month, and on ARV treatment in the previous month

ARV Treatment naïve starts: participants starting ARV treatment in the specified month for the first time

ARV Treatment experienced starts: participants with history of ARV treatment, but first dispensing in the BC HIV Treatment Program in the specified month


Newly Interrupted ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month, but had a record of ARV medication in the previous month, and not deceased or moved out of program, and had contact with the program in the past 5 years.

Net Change: the difference between ARV treatment starts (naïve and experienced) and ARV treatment stops (Deceased, moved out of program, or newly interrupted ARV treatment)






3.1 Distribution of HIV Treatment Program Active Participants July 2025






3.2 Distribution of HIV Treatment Program Active Participants July 2025

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV Treatment Program Active Participants July 2025

FRASER HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE




3.4 Distribution of HIV Treatment Program Active Participants July 2025

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE



*** Please refer to VIHA (432 and 434) on the next page







3.5 Distribution of HIV Treatment Program Active Participants July 2025



VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA

N = 1076



VICTORIA BY POSTAL CODE


N = 525






3.6 Distribution of HIV Treatment Program Active Participants July 2025

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE



4.1 Distribution of Participants by Age & Sex at Birth INTERIOR Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	0 - 29	*	*	0	0	N/A	0	N/A
	30 - 49	*	*	0	14	745	14	<40
	50 - 64	*	*	0	13	740	11	<40
	65+	*	*	0	6	595	5	<40
	Total HSDA:	37	35	0	33	740	30	<40
KOOTENAY BOUNDARY	0 - 29	5	5	0	5	880	*	*
	30 - 49	14	13	0	12	735	*	*
	50 - 64	21	18	0	17	540	*	*
	65+	18	18	0	13	740	*	*
	Total HSDA:	58	54	0	47	710	45	<40
OKANAGAN	0 - 29	15	14	0	15	730	13	<40
	30 - 49	126	118	0	115	700	97	<40
	50 - 64	156	146	0	140	670	126	<40
	65+	87	84	0	80	580	74	<40
	Total HSDA:	384	362	0	350	660	310	<40
THOMPSON/CARIBOO/SHUSWAP	0 - 29	14	12	0	10	680	10	<40
	30 - 49	55	46	0	46	725	41	<40
	50 - 64	87	77	0	69	680	67	<40
	65+	35	35	0	30	695	33	<40
	Total HSDA:	191	170	0	155	680	151	<40
Total HA:		670	621	0	585	680	536	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	35	32	0	30	755	26	<40
	30 - 49	210	190	0	187	710	164	<40
	50 - 64	278	255	0	239	670	217	<40
	65+	147	144	0	129	620	129	<40
Total HA:		670	621	0	585	680	536	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	536	496	0	466	670	429	<40
Female	134	125	0	119	700	107	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	621	56	680	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)



4.2 Distribution of Participants by Program Duration INTERIOR Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	10 years or more	18	16	0	17	720	13	<40
	5 years or more	11	11	0	7	880	9	<40
	<5 years	8	8	0	9	810	8	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	37	35	0	33	740	30	<40
KOOTENAY BOUNDARY	10 years or more	43	40	0	34	675	*	*
	5 years or more	7	6	0	5	780	*	*
	<5 years	8	8	0	8	740	*	*
	Never on ART	0	0	0	0	N/A	*	*
	Total HSDA:	58	54	0	47	710	45	<40
OKANAGAN	10 years or more	244	232	0	220	670	195	<40
	5 years or more	60	56	0	54	685	48	<40
	<5 years	80	74	0	76	625	67	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	384	362	0	350	660	310	<40
THOMPSON/CARIBOO/SHUSWAP	10 years or more	120	106	0	*	*	*	*
	5 years or more	25	21	0	*	*	*	*
	<5 years	46	43	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
	Total HSDA:	191	170	0	155	680	151	<40
Total HA:		670	621	0	585	680	536	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	425	394	0	*	*	*	*
	5 years or more	103	94	0	*	*	*	*
	<5 years	142	133	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
Total HA:		670	621	0	585	680	536	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.3 Distribution of Antiretroviral Treatment Prescribers INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
EAST KOOTENAY	13	30	53	103
KOOTENAY BOUNDARY	18	38	78	141
OKANAGAN	53	335	246	1117
THOMPSON/CARIBOO/SHUSWAP	32	143	152	596
Total:	116	546	529	1957

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
EAST KOOTENAY	5
KOOTENAY BOUNDARY	18
OKANAGAN	60
THOMPSON/CARIBOO/SHUSWAP	46
Total:	129

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.4 Distribution of Participants by Age & Sex at Birth FRASER Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	0 - 29	28	27	*	30	765	26	<40
	30 - 49	112	95	*	80	720	87	<40
	50 - 64	156	143	*	104	625	123	<40
	65+	69	69	*	46	700	65	<40
	Total HSDA:	365	334	<5	260	685	301	<40
FRASER NORTH	0 - 29	47	44	*	43	660	45	<40
	30 - 49	380	339	*	307	700	317	<40
	50 - 64	360	340	*	238	675	315	<40
	65+	176	171	*	107	600	158	<40
	Total HSDA:	963	894	<5	695	680	835	<40
FRASER SOUTH	0 - 29	72	69	*	58	590.5	65	<40
	30 - 49	362	335	*	255	700	330	<40
	50 - 64	393	367	*	254	650	337	<40
	65+	168	163	*	121	550	156	<40
	Total HSDA:	995	934	<5	688	640	888	<40
Total HA:		2323	2162	<5	1643	661	2024	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	147	140	*	131	660	136	<40
	30 - 49	854	769	*	642	700	734	<40
	50 - 64	909	850	*	596	650	775	<40
	65+	413	403	*	274	590	379	<40
Total HA:		2323	2162	<5	1643	661	2024	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	1754	1647	*	1194	650	1538	<40
Female	569	515	*	449	700	486	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	2162	53	670	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
on ART: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
CD4 or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)





4.5 Distribution of Participants by Program Duration FRASER Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	10 years or more	228	213	*	*	*	*	*
	5 years or more	60	46	*	*	*	*	*
	<5 years	77	75	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	365	334	<5	260	685	301	<40
FRASER NORTH	10 years or more	602	568	*	*	*	*	*
	5 years or more	160	140	*	*	*	*	*
	<5 years	201	186	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	963	894	<5	695	680	835	<40
FRASER SOUTH	10 years or more	570	528	*	379	650	490	<40
	5 years or more	168	155	*	102	647	149	<40
	<5 years	257	251	*	202	610	243	<40
	Never on ART	0	0	*	5	429	6	65
	Total HSDA:	995	934	<5	688	640	888	<40
Total HA:		2323	2162	<5	1643	661	2024	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	1400	1309	*	942	680	1195	<40
	5 years or more	388	341	*	256	680	326	<40
	<5 years	535	512	*	436	630	492	<40
	Never on ART	0	0	*	9	550	11	<40
Total HA:		2323	2162	<5	1643	661	2024	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.6 Distribution of Antiretroviral Treatment Prescribers FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
FRASER EAST	30	64	155	558
FRASER NORTH	28	241	268	1661
FRASER SOUTH	42	562	239	1995
Total:	100	867	662	4214

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
FRASER EAST	215
FRASER NORTH	738
FRASER SOUTH	480
Total:	1433

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.7 Distribution of Participants by Age & Sex at Birth VANCOUVER COASTAL Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	0 - 29	11	10	0	10	800	6	<40
	30 - 49	79	71	0	61	710	67	<40
	50 - 64	131	119	0	80	705	113	<40
	65+	96	90	0	78	670	85	<40
	Total HSDA:	317	290	0	229	700	271	<40
RICHMOND	0 - 29	9	7	*	9	720	8	<40
	30 - 49	65	56	*	57	600	55	<40
	50 - 64	78	73	*	62	670	69	<40
	65+	28	27	*	26	540	24	<40
	Total HSDA:	180	163	<5	154	615	156	<40
VANCOUVER	0 - 29	108	100	*	96	700	97	<40
	30 - 49	1144	1012	*	844	690	982	<40
	50 - 64	1480	1368	*	1023	610	1326	<40
	65+	748	712	*	470	610	699	<40
	Total HSDA:	3480	3192	<5	2433	640	3104	<40
Total HA:		3977	3645	<5	2816	645	3531	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	128	117	*	115	720	111	<40
	30 - 49	1288	1139	*	962	680	1104	<40
	50 - 64	1689	1560	*	1165	620	1508	<40
	65+	872	829	*	574	610	808	<40
Total HA:		3977	3645	<5	2816	645	3531	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	3484	3202	*	2358	640	3115	<40
Female	493	443	*	458	670	416	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	3645	56	650	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.8 Distribution of Participants by Program Duration VANCOUVER COASTAL Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	10 years or more	227	204	0	*	*	194	<40
	5 years or more	43	42	0	*	*	37	<40
	<5 years	47	44	0	*	*	40	<40
	Never on ART	0	0	0	*	*	0	N/A
	Total HSDA:	317	290	0	229	700	271	<40
RICHMOND	10 years or more	100	93	*	*	*	*	*
	5 years or more	35	29	*	*	*	*	*
	<5 years	45	41	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	180	163	<5	154	615	156	<40
VANCOUVER	10 years or more	2447	2271	*	1633	620	2204	<40
	5 years or more	538	467	*	367	750	444	<40
	<5 years	495	454	*	426	660	448	<40
	Never on ART	0	0	*	7	480	8	<40
	Total HSDA:	3480	3192	<5	2433	640	3104	<40
Total HA:		3977	3645	<5	2816	645	3531	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	2774	2568	*	1868	625	2484	<40
	5 years or more	616	538	*	428	740	510	<40
	<5 years	587	539	*	511	650	528	<40
	Never on ART	0	0	*	9	480	9	<40
Total HA:		3977	3645	<5	2816	645	3531	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.9 Distribution of Antiretroviral Treatment Prescribers VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH SHORE/COAST GARIBALDI	38	60	204	582
RICHMOND	9	113	49	345
VANCOUVER	205	5430	706	12264
Total:	252	5603	959	13191

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	54

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.10 Distribution of Participants by Age & Sex at Birth VANCOUVER ISLAND Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	0 - 29	8	6	*	5	810	6	<40
	30 - 49	85	76	*	53	630	68	<40
	50 - 64	146	135	*	68	680	113	<40
	65+	90	87	*	41	530	82	<40
	Total HSDA:	329	304	<5	167	600	269	<40
NORTH VANCOUVER ISLAND	0 - 29	5	5	0	*	*	*	*
	30 - 49	29	25	0	*	*	*	*
	50 - 64	53	49	0	*	*	*	*
	65+	35	33	0	*	*	*	*
	Total HSDA:	122	112	0	65	650	90	<40
SOUTH VANCOUVER ISLAND	0 - 29	29	25	0	12	515	20	<40
	30 - 49	203	177	0	71	600	153	<40
	50 - 64	313	294	0	94	610	257	<40
	65+	166	164	0	34	700	159	<40
	Total HSDA:	711	660	0	211	630	589	<40
Total HA:		1162	1076	<5	443	620	948	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	42	36	*	21	540	30	<40
	30 - 49	317	278	*	143	610	243	<40
	50 - 64	512	478	*	188	625	409	<40
	65+	291	284	*	91	640	266	<40
Total HA:		1162	1076	<5	443	620	948	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	969	899	*	346	600	791	<40
Female	193	177	*	97	680	157	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	1076	58	620	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)



4.11 Distribution of Participants by Program Duration VANCOUVER ISLAND Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	10 years or more	225	207	*	103	600	188	<40
	5 years or more	55	52	*	31	750	41	<40
	<5 years	49	45	*	33	560	40	<40
	Never on ART	0	0	*	0	N/A	0	N/A
	Total HSDA:	329	304	<5	167	600	269	<40
NORTH VANCOUVER ISLAND	10 years or more	91	82	0	41	610	65	<40
	5 years or more	12	12	0	8	655	8	<40
	<5 years	19	18	0	16	690	17	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	122	112	0	65	650	90	<40
SOUTH VANCOUVER ISLAND	10 years or more	434	417	0	114	660	376	<40
	5 years or more	131	110	0	45	680	94	<40
	<5 years	146	133	0	52	555	119	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	711	660	0	211	630	589	<40
Total HA:		1162	1076	<5	443	620	948	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	750	706	*	258	620	629	<40
	5 years or more	198	174	*	84	690	143	<40
	<5 years	214	196	*	101	580	176	<40
	Never on ART	0	0	*	0	N/A	0	N/A
Total HA:		1162	1076	<5	443	620	948	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.12 Distribution of Antiretroviral Treatment Prescribers VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
CENTRAL VANCOUVER ISLAND	66	211	214	984
NORTH VANCOUVER ISLAND	32	62	155	367
SOUTH VANCOUVER ISLAND	48	612	241	2083
Total:	146	885	610	3434

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
CENTRAL VANCOUVER ISLAND	93
NORTH VANCOUVER ISLAND	50
SOUTH VANCOUVER ISLAND	129
Total:	272

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.13 Distribution of Participants by Age & Sex at Birth NORTHERN Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	Total HSDA:	45	38	0	43	590	33	<40
NORTH WEST	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	Total HSDA:	74	66	0	64	605	57	<40
NORTHERN INTERIOR	0 - 29	7	6	0	7	710	7	<40
	30 - 49	68	56	0	60	700	51	<40
	50 - 64	69	65	0	63	510	56	<40
	65+	34	30	0	34	550	28	<40
	Total HSDA:	178	157	0	164	585	142	<40
Total HA:		297	261	0	271	590	232	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	13	11	0	13	600	13	<40
	30 - 49	109	89	0	94	670	79	<40
	50 - 64	124	114	0	114	545	97	<40
	65+	51	47	0	50	525	43	<40
Total HA:		297	261	0	271	590	232	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	196	176	0	179	590	155	<40
Female	101	85	0	92	590	77	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	261	54	600	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.14 Distribution of Participants by Program Duration NORTHERN Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	10 years or more	21	*	0	20	565	13	<40
	5 years or more	6	*	0	5	440	5	<40
	<5 years	18	*	0	18	615	15	<40
	Never on ART	0	*	0	0	N/A	0	N/A
	Total HSDA:	45	38	0	43	590	33	<40
NORTH WEST	10 years or more	51	44	0	43	610	37	<40
	5 years or more	8	8	0	7	630	8	<40
	<5 years	15	14	0	14	575	12	56
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	74	66	0	64	605	57	<40
NORTHERN INTERIOR	10 years or more	116	106	0	*	*	*	*
	5 years or more	37	30	0	*	*	*	*
	<5 years	25	21	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
	Total HSDA:	178	157	0	164	585	142	<40
Total HA:		297	261	0	271	590	232	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	188	166	0	*	*	*	*
	5 years or more	51	42	0	*	*	*	*
	<5 years	58	53	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
Total HA:		297	261	0	271	590	232	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.15 Distribution of Antiretroviral Treatment Prescribers NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH EAST	2	*	37	50
NORTH WEST	13	*	93	177
NORTHERN INTERIOR	21	*	129	555
Total:	36	221	259	782

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH EAST	8
NORTH WEST	29
NORTHERN INTERIOR	24
Total:	61

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth

HA	HSDA	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
INTERIOR	EAST KOOTENAY	*	*	0	*	*	*	*
	KOOTENAY BOUNDARY	*	*	0	*	*	*	*
	OKANAGAN	*	*	0	*	*	*	*
	THOMPSON/CARIBOO/SHUSWAP	*	*	0	*	*	*	*
	Total HA:	52	48	0	43	550	38	<40
FRASER	FRASER EAST	30	26	0	23	640	23	<40
	FRASER NORTH	42	39	0	32	480	34	<40
	FRASER SOUTH	60	55	0	41	558	51	<40
	Total HA:	132	120	0	96	559	108	<40
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	28	26	0	23	750	22	<40
	RICHMOND	5	5	0	5	560	5	<40
	VANCOUVER	362	337	0	343	490	314	<40
	Total HA:	395	368	0	371	500	341	<40
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	45	40	0	23	590	38	<40
	NORTH VANCOUVER ISLAND	16	13	0	11	440	9	<40
	SOUTH VANCOUVER ISLAND	44	36	0	15	590	32	<40
	Total HA:	105	89	0	49	580	79	<40
NORTHERN	NORTH EAST	11	9	0	11	450	7	<40
	NORTH WEST	35	30	0	31	540	26	<40
	NORTHERN INTERIOR	64	56	0	58	550	52	<40
	Total HA:	110	95	0	100	535	85	<40
Total:	794	720	0	659	530	651	<40	

Sex at Birth	# Enrolled	# on Antiretroviral Treatment	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	498	456	0	405	510	413	<40
Female	296	264	0	254	559	238	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total:	720	55	540	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
on Antiretroviral Treatment: defined as # of Participants being on antiretroviral treatment in the specified month
CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)





BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

Funding for the BC Centre for Excellence in HIV/AIDS and HIV Drug Treatment Program provided in-part by:

